Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Proceedings Article
  • Published:

Novel strategies in treatment of acute promyelocytic leukemia

Leukemia Supplements volume 1, pages S18–S19 (2012)Cite this article

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by t(15;17) and a life-threatening coagulopathy. Once highly fatal, nowadays standard treatment approaches with all-trans retinoic acid (ATRA) along with chemotherapy allows curing up to 80–85% of cases. In the past decade, arsenic trioxide used alone or in combination with ATRA has demonstrated high efficacy in APL, and is currently regarded as the gold standard for treatment of relapsed cases. Chemotherapy-free approaches based on the combination of arsenic trioxide and ATRA are currently being tested against standard ATRA and chemotherapy in randomized clinical trials for frontline therapy of APL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bernard J . History of promyelocytic leukaemia. Leukemia 1994; 8 (Suppl 2): S1–S5.

    Google Scholar 

  2. Wang ZY, Chen Z . Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505–2515.

    Article  CAS  Google Scholar 

  3. Sanz MA, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 2008; 112: 3130–3134.

    Article  CAS  Google Scholar 

  4. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al., Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010; 116: 3171–3179.

    Article  CAS  Google Scholar 

  5. Zhang P, Wang SY, Hu LH . Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996; 17: 58–62.

    Google Scholar 

  6. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328–5335.

    Article  CAS  Google Scholar 

  7. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469–3473.

    Article  CAS  Google Scholar 

  8. Sanz MA, Lo-Coco F . Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011; 29: 495–503.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biopathology, University of Rome “Tor Vergata”, Rome, Italy

    F Lo-Coco & L Cicconi

  2. Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy

    F Lo-Coco & L Cicconi

Authors
  1. F Lo-Coco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Cicconi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Lo-Coco.

Ethics declarations

Competing interests

FL-C received speaker's honoraria from Cephalon. LC declares no conflict of interest.

Additional information

This article was published as part of a supplement that was supported by Novartis, MSD Italia, Roche, Celgene, GlaxoSmithKline, Sanofi, Gilead, Adienne, Italfarmaco, Pierre Fabre Pharmaceuticals with an unrestricted educational contribution to AREO—Associazione Ricerche Emato-Oncologiche (Genoa) and AMS—Associazione Malattie del Sangue (Milan) for the purpose of advancing research in acute and chronic leukemia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lo-Coco, F., Cicconi, L. Novel strategies in treatment of acute promyelocytic leukemia. Leukemia Suppl 1 (Suppl 2), S18–S19 (2012). https://doi.org/10.1038/leusup.2012.12

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leusup.2012.12

Keywords

Search

Advanced search

Quick links